In conclusion, our study demonstrated that MEX3A, a novel carcinogenic RBP in BC, could promote tumor cell progression through mediated IGFBP4 post-transcriptional metabolism, ultimately affecting survival in BC patients. Here, IGFBP4 is linked to neoplasm.